Allergan, Inc. (AGN): No Sign of a Slowdown at This Recession Resistant Company

Page 1 of 2

I must confess I am finding the current market to be one of the most frustrating periods of my investing life. I’ve always liked a defensive growth stock, but nowadays they seem to be so expensive that the only thing left to do is refrain from buying and sulk in the corner for a while. However, I can’t complain too much about Allergan, Inc. (NYSE:AGN), as it’s a stock I held during its sterling run lately. I like the stock, but it is fairly valued now and on a risk reward basis I won’t be buying back in just yet.

Allergan, Inc. (NYSE:AGN)Allergan, Inc. (NYSE:AGN) Delivers Growth

I initially covered the stock in an article linked here, which is useful as a primer for research. In order to assess current prospects I’ve tabulated what Allergan forecast for the full year in 2012 alongside what it achieved and then the guidance for 2013. The starred figures in the middle column are for those products that beat the mid-point of full year guidance from Q3.

Allergan is offering a mix of mid-single digit top line growth along with mid-teens EPS growth. All of this is fine but, in my opinion, it doesn’t justify a trailing PE ratio of 31 and a forward PE of 22. Moreover, the forecast figure of around $1 billion in free cash flow puts it on a free cash flow yield of around 3.2%. It’s hardly cheap.

Botox Driving Growth

With that said, investors need to appraise the long term prospects for the company, and they do look solid.  The biggest single product is the market leading neuromodulator Botox. AGN claims to have around 77% of the global market and is gaining share in therapeutic uses but losing it in aesthetics. The plan is to increase sales in new or expanding indications like migraine, spasticity and bladder treatments.

Obviously with such a dominant position the concern is that it could lose some share in future. Indeed, Valeant Pharmaceuticals Intl Inc (NYSE:VRX) is buying Medicis partly because it wants to expand its dermatology operations with Dysport (the key rival to Botox). Furthermore, Merz Pharma will be allowed to re-commercialize Xeomin for aesthetics in the current quarter. Listening to the commentary around the results, AGN seem to think it may gain some market share from Dysport as a result of the impending takeover but that it will lose some thanks to Xeomin’s re-introduction; this is baked into the guidance. Given that Botox has 84% of the US aesthetic market it’s not surprising to see some pressure. AGN also faces competition from Johnson & Johnson (NYSE:JNJ) , which has an anti-wrinkle product that it obtained from the acquisition of Metnor. However, JNJ hasn’t exactly set the world on fire with its skin care numbers lately.

Turning back to Botox, I’m a great believer in the idea that neuromodulators have a bright future for aesthetic purposes. More old people, more divorces, more wealthy women running around without kids, is there a more perfect climate for more plastic surgery? Indeed, AGN pointed out that Italy, Spain and France (challenged economies in Europe) reported strong numbers.

Looking at Botox longer term, the growth is expected to occur within therapeutic, and it has been obtaining approvals for its migraines and bladder treatments in various countries recently. However, the key news recently has been the FDA approval for use in overactive bladder treatment. Prospects look good for Botox, and investors can feel confident.

Page 1 of 2
blog comments powered by Disqus
Insider Monkey Headlines
Insider Monkey Small Cap Strategy
Insider Monkey Small Cap Strategy

Insider Monkey beat the market by 52 percentage points in 24 months Click to see monthly returns in table format!

Lists

50 Crazy Facts About Japan You Won’t Believe

Top 10 Least Expensive Hybrid Cars to Save the Planet With

The 10 Biggest ‘Gate’ Controversies in History

The 10 States with the Highest Nursing Shortages Leaving Their Hospitals Depleted

The 10 Best Value Investment Blogs that Every Investor Must Read

The 6 Cheapest Boarding Schools in Europe 2015

The 5 Most Expensive Cars To Insure in the World

The 10 Most Common Genetically Modified Foods

10 Self-Made Billionaires Who Came From Nothing

The 10 Most Expensive Cities to Live in North America

The 13 Most Expensive Headphones in the World to Represent

The Top 20 Wealthiest Soccer Teams in 2014

4 BuzzWorthy Cannabis Stocks And Some Smoking Derivative Plays

The 10 Healthiest Fast Food Chains in America to Dine At

The 5 Most Expensive Cat Food Brands You Can Spoil Your Kitty With

The 6 Best eCommerce Platforms for Small Businesses

The 10 Worst Mistakes an Entrepreneur Can Make

The 5 Most OP Characters in League of Legends to Carry Games and Crush Foes With

The 5 Best Foods to Eat Before Running that Will Help You Pound the Pavement

10 Glaring Plot Holes in The Walking Dead that a Zombie-Filled Bus Could Drive Through

The 5 Biggest Celebrity Stoners Who Love Their Reefer

The 10 Most Overrated Movies Of All Time by Out-of-Touch Critics

Top 6 Least Expensive Cruise Destinations For 2015 that Will Take You to Paradise

10 States with Lowest Substance Abuse Rates in America

The 14 Most Watched TV Finales Ever

The 10 Best Selling Role Playing Games of All Time for PC

10 Most Influential Papers In Economics

Top 8 Biggest Charities in the US

10 Worst Celebrity Career Moves Ever

Top 10 Best Paid Tennis Stars in the World

10 Cities with High Demand for Nurses

6 of the Worst Greeting Card Messages Ever Crafted

How to Make Money in ArcheAge and Build Your Empire

10 Foods To Eat To Lower Cholesterol Levels

The 10 Most Hated Television Characters of All Time

The 30 Worst Halloween Costume Ideas Ever Brought to Horrible Life

10 Vocational Skills in Demand Today with Jobs Waiting to be Filled

10 Best Places to Visit in Central and South America

The 10 Greatest Empires in History Which Nearly Conquered the World

The 6 Cheapest Boarding Schools In America 2015

5 Clear Reasons LoL is Better than DotA, Continues to Rule MOBAs

The Only 9 Teams with a Chance to Win the Super Bowl

The 15 Most Common Phobias in America that Induce Fits of Panic

Top 6 Least Expensive Tourist Destinations in 2014

Jim Goetz, Peter Fenton, Jim Breyer: Top 6 Venture Investors for 2014

Top 15 Billionaires in 2014

5 Pitfalls To Avoid When Buying a Franchise

Top 20 Medical Schools in the US – 2014 Rankings

4 Business Strategies that Turned Jamie Oliver into the World’s Richest Chef

6 Qualities That Make You A Good Team Player

Subscribe

Enter your email:

Delivered by FeedBurner

X

Thanks! An email with instructions is sent to !

Your email already exists in our database. Click here to go to your subscriptions

Insider Monkey returned 47.6% in its first year! Wondering How?

Download a complete edition of our newsletter for free!